Medifast Inc (MED) stock
MEDNYSEMiscellaneous Food Preparations & Kindred ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 10/3064% below fair value
$12.97+0.11 (+0.86%)
Close on Nov 13, 2026Market cap $145.04MP/E –Yield 0.00%
Medifast EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Medifast's EPS for the twelve months ending Sep 30, 2026 was -$3.69, down 37000.0% year over year. For fiscal 2025 it was -$1.70, down 994.7% from the year before. The highest annual figure on record is $13.89 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.70 | -994.7% |
| FY2024 | Dec 31, 2024 | $0.19 | -97.9% |
| FY2023 | Dec 31, 2023 | $9.10 | -28.5% |
| FY2022 | Dec 31, 2022 | $12.73 | -8.4% |
| FY2021 | Dec 31, 2021 | $13.89 | +60.0% |
| FY2020 | Dec 31, 2020 | $8.68 | +35.0% |
| FY2019 | Dec 31, 2019 | $6.43 | +39.2% |
| FY2018 | Dec 31, 2018 | $4.62 | +101.7% |
| FY2017 | Dec 31, 2017 | $2.29 | +53.7% |
| FY2016 | Dec 31, 2016 | $1.49 | -10.2% |
| FY2015 | Dec 31, 2015 | $1.66 | +61.2% |
| FY2014 | Dec 31, 2014 | $1.03 | -40.5% |
| FY2013 | Dec 31, 2013 | $1.73 | +49.1% |
| FY2012 | Dec 31, 2012 | $1.16 | -11.5% |
| FY2011 | Dec 31, 2011 | $1.31 | -3.0% |
| FY2010 | Dec 31, 2010 | $1.35 | +75.3% |
| FY2009 | Dec 31, 2009 | $0.77 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.57 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.28 | -227.3% |
| Q1 FY2026 | Mar 31, 2026 | -$0.19 | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.65 | -2457.1% |
| Q3 FY2025 | Sep 30, 2025 | -$0.21 | -310.0% |
| Q2 FY2025 | Jun 30, 2025 | $0.22 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.07 | -109.2% |
| Q4 FY2024 | Dec 31, 2024 | $0.07 | -87.3% |
| Q3 FY2024 | Sep 30, 2024 | $0.10 | -95.3% |
| Q2 FY2024 | Jun 30, 2024 | -$0.75 | -127.1% |
| Q1 FY2024 | Mar 31, 2024 | $0.76 | -79.3% |
| Q4 FY2023 | Dec 31, 2023 | $0.55 | -77.2% |
| Q3 FY2023 | Sep 30, 2023 | $2.12 | -35.2% |
| Q2 FY2023 | Jun 30, 2023 | $2.77 | -19.0% |
| Q1 FY2023 | Mar 31, 2023 | $3.67 | +2.2% |
| Q4 FY2022 | Dec 31, 2022 | $2.41 | -16.9% |
| Q3 FY2022 | Sep 30, 2022 | $3.27 | -8.1% |
| Q2 FY2022 | Jun 30, 2022 | $3.42 | -13.6% |
| Q1 FY2022 | Mar 31, 2022 | $3.59 | +3.8% |
| Q4 FY2021 | Dec 31, 2021 | $2.90 | +22.9% |
| Q3 FY2021 | Sep 30, 2021 | $3.56 | +22.3% |
| Q2 FY2021 | Jun 30, 2021 | $3.96 | +112.9% |
| Q1 FY2021 | Mar 31, 2021 | $3.46 | +121.8% |
| Q4 FY2020 | Dec 31, 2020 | $2.36 | +42.2% |
| Q3 FY2020 | Sep 30, 2020 | $2.91 | +120.5% |
| Q2 FY2020 | Jun 30, 2020 | $1.86 | +6.3% |
| Q1 FY2020 | Mar 31, 2020 | $1.56 | -8.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.66 | +27.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.32 | +15.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.75 | +50.9% |
| Q1 FY2019 | Mar 31, 2019 | $1.70 | +68.3% |
| Q4 FY2018 | Dec 31, 2018 | $1.30 | +116.7% |
| Q3 FY2018 | Sep 30, 2018 | $1.14 | +107.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.16 | +84.1% |
| Q1 FY2018 | Mar 31, 2018 | $1.01 | +98.0% |
| Q4 FY2017 | Dec 31, 2017 | $0.60 | +76.5% |
| Q3 FY2017 | Sep 30, 2017 | $0.55 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.63 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.51 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.34 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?